NextGen Sciences, Berg Diagnostics
Neal Siegel, Glenn Barney, Hiroshi Saito, Jay Moyes, Michael Marletta, Richard Lerner
In about a month, the company plans to offer four assays targeted to neurodegenerative disease and heart disease, its CEO said.
The assays will be used by the drug company for preclinical and clinical studies.
Thermo Fisher's BRIMS Center is collaborating with NextGen Sciences to improve that company's suite of biomarker services.
The sale, for undisclosed cash and royalties, completes NextGen's realignment toward biomarker services.
The New York Times Magazine examines gender discrimination at the Salk Institute.
Science reports that MD Anderson Cancer Center has dismissed three researchers over foreign tie concerns.
A second death in gene therapy trial for type 1 spinal muscular atrophy is under investigation, according to Reuters.
In PLOS this week: antibiotic resistance patterns in Escherichia coli, a dozen genetic loci tied to varicose vein risk, and more.